To exclude the effect of other variables on the more severe cognitive decline observed in the 2020-GROUP, we investigated whether there were significant differences in the frequency of different dementia subtypes (considering probable Alzheimer’s disease, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, and mild cognitive impairment) and in the use of cholinesterase inhibitors and/or memantine. The gene discussed is BCHE; the disease is vascular dementia.